

REMARKS

The Examiner has restricted this application to one of the following inventions under 35 U.S.C. § 121:

Group I is claims 1-21, drawn to a purified and isolated nucleic acid molecule capable of directing transcription of operably linked sequences consistent with CA125/M17S2 expression.


Group II is claims 22 and 23, drawn to a method of providing a nucleotide sequence to treat ovarian cancer comprising administering a nucleic acid construct comprising a therapeutic gene under the control of CA125/M17S2 promoter.

The Applicants provisionally elect with traverse, Group I, Claims 1-21, drawn to a purified and isolated nucleic acid molecule capable of directing transcription of operably linked sequences consistent with CA125/M17S2 expression. Applicants request rejoinder as both groups relate to a single novel compound and methods of use of that compound.

No fees or extensions of time are believed to be due in connection with this amendment; however, consider this a request for any extension inadvertently omitted, and charge any additional fees to Deposit Account No. 26-0084.

Reconsideration and allowance is respectfully requested.

Respectfully submitted,



HEIDI S. NEBEL, Reg. No. 37,719
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No: (515) 288-3667
Fax No: (515) 288-1338
CUSTOMER NO: 27407
Attorneys of Record

- pw -